Former Chief Commercial Officer · CorMedix Inc. (CRMD)

Thomas Nusbickel

FY2021 is the first fiscal year CompBrief holds for Thomas Nusbickel as a named executive officer of CorMedix; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,876,582

Salary $233,654Stock awards $0Bonus $75,000

2nd of 6 named executive officers at CorMedix by FY2021 total.

6 named officers on file for CorMedix, FY2021

Thomas Nusbickel’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CorMedix’s whole pay program stands against its peers

  • CorMedix’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CRMD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed August 30, 2022 (DEF 14A).

Free

Get Thomas Nusbickel’s full pay file as a PDF — free

More than this page: up to 10 years of Thomas’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Thomas Nusbickel compensation by year

CorMedix Summary Compensation Table · the one fiscal year held
In US dollars, as CorMedix reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$233,654
Bonus$75,000
Stock awards$0
Option awards$1,540,265
Non-equity incentive$0
Pension and deferred compensation$0
All other$27,663
Total$1,876,582

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CorMedix Inc. DEF 14A filed August 30, 2022, accession 0001213900-22-052252, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CorMedix Inc. filed document, accession 0001213900-22-052252. Every figure is read from that document and cited to the page and table it appears in. Filed August 30, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option100,000—$7.56
Option167,500—$7.56

Per the Outstanding Equity Awards at Fiscal Year-End table in CorMedix Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

CorMedix’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Khoso BaluchFormer Chief Executive Officer$2,596,173
Thomas Nusbickel · this pageFormer Chief Commercial Officer$1,876,582
Phoebe MountsExecutive Vice President and General Counsel and Head of Regulatory, Compliance, Legal and Technical Operations$1,613,097
Matthew DavidExecutive Vice President and Chief Financial Officer$1,423,302
John ArmstrongFormer Executive Vice President for Technical Operations$1,339,348
Elizabeth Masson-HurlburtExecutive Vice President and Head of Clinical Operations$1,136,328

The full CorMedix compensation record

free company brief

This page is one person within CorMedix's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CorMedix's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Thomas Nusbickel's compensation dossier · One-time report. No refunds.